Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis Segurança na mudança direta de natalizumabe para fingolimode em um grupo de pacientes com esclerose múltipla e positivos para JCV

ABSTRACT Objective: To assess safety of the switch between natalizumab and fingolimod without a washout period. Prospective data Methods: on 25 JCV positive patients who underwent this medication switch were collected and analyzed. After a median period of nine Results: months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion: Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.Keywords: multiple sclerosis; natalizumab; fingolimod hydrochloride; therapeutics. RESUMO Objetivo: Avaliar a seguranca na mudanca entre natalizumabe e fingolimode sem periodo de washout. Dados prospectivos de Metodos: 25 pacientes positivos para virus JC que tiveram sua medicacao modificada foram coletados e analisados. Resultados: Apos uma mediana de nove meses da troca de medicacao, nao havia aspectos de seguranca a relatar. Os pacientes estavam com bom controle da doenca e nao foram relatados eventos adversos. Conclusao: Washout pode nao ser necessario na pratica diaria para a mudanca entre natalizumabe e fingolimode. No entanto, expertise no manejo de esclerose multipla e essencial para esta troca entre medicacoes. Palavras-chave: esclerose multipla; natalizumab; cloridrato de fingolimode; terapeutica.